Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial

被引：0

作者：

Broeckelmann, Paul J. ^{[1
]}

Buehnen, Ina ^{[1
]}

Herhaus, Peter ^{[2
]}

Meissner, Julia ^{[3
]}

Trautmann-Grill, Karolin ^{[4
]}

Mueller, Horst ^{[1
]}

Fuchs, Michael ^{[5
,6
]}

von Tresckow, Bastian ^{[7
]}

Borchmann, Peter ^{[8
]}

Engert, Andreas ^{[1
]}

Behringer, Karolin ^{[1
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, German Hodgkin Study Grp GHSG, Cologne, Germany

[2] Tech Univ Munich, Clin & Policlin Internal Med 3, Sch Med, Klinikum Rechts Isar, Munich, Germany

[3] Univ Hosp Heidelberg, Med 5, Heidelberg, Germany

[4] Univ Hosp Carl Gustav Carus, Med Clin 1, Dresden, Germany

[5] Univ Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Dept Internal Med 1, Med Fac, Cologne, Germany

[6] Univ Hosp Cologne, Cologne, Germany

[7] West German Canc Ctr Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany

[8] Univ Hosp Cologne, Dept Internal Med 1, German Hodgkin Study Grp GHSG, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188734

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial [J].

Broeckelmann, Paul J. ;

Teesink, Sophie ;

Visser, Lydia ;

Voltin, Conrad-Amadeus ;

Kaul, Helen ;

Schloesser, Hans ;

Kroesen, Bart-Jan ;

Kobe, Carsten ;

Borchmann, Peter ;

Diepstra, Arjan ;

Plattel, Wouter .

BLOOD, 2024, 144 :3044-3045

[22] CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab plus Ipilimumab in High Tumor Mutational Burden Advanced NSCLC [J].

Brahmer, J. ;

Schenker, M. ;

Lee, K. H. ;

Provencio, M. ;

Nishio, M. ;

Lesniewski-Kmak, K. ;

Sangha, R. ;

Ahmed, S. ;

Raimbourg, J. ;

Feeney, K. ;

Corre, R. ;

Franke, F. ;

Richardet, E. ;

Penrod, J. ;

Yuan, Y. ;

Nathan, F. ;

Bhagavatheeswaran, P. ;

De Rosa, M. ;

Taylor, F. ;

Lawrance, R. ;

Reck, M. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S332-S332

[23] Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3 [J].

Makharadze, Tamta ;

Quek, Ruben G. W. ;

Melkadze, Tamar ;

Gogishvili, Miranda ;

Ivanescu, Cristina ;

Giorgadze, Davit ;

Dvorkin, Mikhail ;

Penkov, Konstantin ;

Laktionov, Konstantin ;

Nemsadze, Gia ;

Nechaeva, Marina ;

Rozhkova, Irina ;

Kalinka, Ewa ;

Gessner, Christian ;

Moreno-Jaime, Brizio ;

Passalacqua, Rodolfo ;

Konidaris, Gerasimos ;

Rietschel, Petra ;

Gullo, Giuseppe .

CANCER, 2023, 129 (14) :2256-2265

[24] Changes in patient-reported outcomes during the SENSE Trial: first-line treatment with 2 NRTIs plus etravirine or efavirenz for 48 weeks [J].

Miralles Alvarez, C. ;

Clotet, B. ;

Nelson, M. ;

Uglietti, A. ;

Hill, A. ;

van Delft, Y. ;

Marks, S. .

ANTIVIRAL THERAPY, 2011, 16 :A64-A64

[25] Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial [J].

Broeckelmann, Paul J. ;

Boell, Boris ;

Molin, Daniel ;

Schneider, Gundolf ;

Leppae, Sirpa ;

Meissner, Julia ;

Kamper, Peter ;

Hutchings, Martin ;

Christensen, Jacob Haaber ;

Schnetzke, Ulf ;

Fuchs, Michael ;

Eichenauer, Dennis A. ;

von Tresckow, Bastian ;

Kaul, Helen ;

Borchmann, Peter ;

Fossa, Alexander .

BLOOD, 2024, 144 :3055-3055

[26] Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes [J].

Blanco, Remei ;

Domine, Manuel ;

Gonzalez, Jose Luis ;

Loutfi, Sami ;

Alfaro, Jordi ;

Saldana, Juana ;

Rubio, Jaime ;

Campos, Begona ;

Hidalgo, Julia ;

Barba, Andres ;

Marquez, Diego ;

Martin, Maria ;

Olaverri, Amaya ;

Nadal, Ernest .

LUNG CANCER, 2023, 183

[27] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial [J].

Vogel, Arndt ;

Qin, Shukui ;

Kudo, Masatoshi ;

Su, Yun ;

Hudgens, Stacie ;

Yamashita, Tatsuya ;

Yoon, Jung-Hwan ;

Fartoux, Laetitia ;

Simon, Krzysztof ;

Lopez, Carlos ;

Sung, Max ;

Mody, Kalgi ;

Ohtsuka, Tatsuroh ;

Tamai, Toshiyuki ;

Bennett, Lee ;

Meier, Genevieve ;

Breder, Valery .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (08) :649-658

[28] APPROACH AND FEASIBILITY OF PATIENT-REPORTED OUTCOMES IN A PHASE III CLINICAL TRIAL FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN CHILDREN AND ADOLESCENTS [J].

Castellino, S. M. ;

Henderson, T. O. ;

Keller, F. ;

Kelly, K. ;

Curtis, R. ;

Conti, R. M. ;

Parsons, S. K. .

HAEMATOLOGICA, 2016, 101 :37-37

[29] Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial [J].

Ooki, Akira ;

Morita, Satoshi ;

Iwamoto, Shigeyoshi ;

Hara, Hiroki ;

Tanioka, Hiroaki ;

Satake, Hironaga ;

Kataoka, Masato ;

Kotaka, Masahito ;

Kagawa, Yoshinori ;

Nakamura, Masato ;

Shingai, Tatsushi ;

Ishikawa, Masashi ;

Miyake, Yasuhiro ;

Suto, Takeshi ;

Hashiguchi, Yojiro ;

Yabuno, Taichi ;

Sakamoto, Junichi ;

Tsuji, Akihito ;

Ando, Masahiko ;

Yamaguchi, Kensei .

CANCER MEDICINE, 2020, 9 (05) :1779-1789

[30] Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK plus NSCLC [J].

Mazieres, J. ;

Iadeluca, L. ;

Shaw, A. ;

Solomon, B. ;

Bauer, T. ;

De Marinis, F. ;

Felip, E. ;

Goto, Y. ;

Kim, D. ;

Mok, T. ;

Reisman, A. ;

Thurm, H. ;

Polli, A. ;

Liu, G. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S175-S176

← 1 2 3 4 5 →